Zai Lab Ltd
ZLAB22.030USD
+0.140+0.64%
交易中 （美东）报价延迟15分钟
2.44B总市值
亏损市盈率 TTM
关于 Zai Lab Ltd 公司
再鼎医药是一家主要从事生物制药的控股公司。公司致力于通过产品发现、开发和商业化来解决肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病领域尚未满足的医疗需求。公司拥有一系列从发现阶段到后期临床项目的专利候选药物。其中包括 ZEJULA、OPTUNE、QINLOCK、NUZYRA 和 VYVGART 等。
Zai Lab Ltd简介
公司代码ZLAB
公司名称Zai Lab Ltd
上市日期Sep 28, 2020
CEODr. Ying (Samantha) Du, Ph.D.
员工数量1869
证券类型Depository Receipt
年结日Sep 28
公司地址Building B, 899 Halei Road, Pudong
城市SHANGHAI
上市交易所NASDAQ Global Market Consolidated
国家China
邮编201203
电话862161632588
网址https://www.zailaboratory.com/
公司代码ZLAB
上市日期Sep 28, 2020
CEODr. Ying (Samantha) Du, Ph.D.
Zai Lab Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+12.18%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
86.60K
+13.05%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-7.83%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
17.44K
-1.36%
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
Mr. Michel Pericles Vounatsos
Mr. Michel Pericles Vounatsos
Independent Director
Independent Director
--
--
Dr. Richard B. Gaynor, M.D.
Dr. Richard B. Gaynor, M.D.
Independent Director
Independent Director
--
--
Ms. Leung (Nisa Bernice) Wing-Yu
Ms. Leung (Nisa Bernice) Wing-Yu
Independent Director
Independent Director
--
--
Mr. Peter Karl Wirth, J.D.
Mr. Peter Karl Wirth, J.D.
Independent Director
Independent Director
--
--
Ms. Christine Chiou
Ms. Christine Chiou
Senior Vice President, Head - Investor Relations
Senior Vice President, Head - Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+12.18%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
86.60K
+13.05%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-7.83%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
17.44K
-1.36%
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
Mr. Michel Pericles Vounatsos
Mr. Michel Pericles Vounatsos
Independent Director
Independent Director
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
业务USD
名称
营收
占比
ZEJULA
41.04M
37.62%
VYVGART
26.50M
24.29%
NUZYRA
14.29M
13.10%
Optune
12.36M
11.33%
QINLOCK
8.54M
7.83%
其他
6.36M
5.83%
地区USD
名称
营收
占比
China (Mainland)
109.98M
0.00%
业务
地区
业务USD
名称
营收
占比
ZEJULA
41.04M
37.62%
VYVGART
26.50M
24.29%
NUZYRA
14.29M
13.10%
Optune
12.36M
11.33%
QINLOCK
8.54M
7.83%
其他
6.36M
5.83%
股东统计
更新时间: 10月31日 周五
更新时间: 10月31日 周五
持股股东
股东类型
持股股东
持股股东
占比
Capital World Investors
5.40%
RTW Investments L.P.
4.95%
Fidelity Management & Research Company LLC
4.37%
ClearBridge Investments, LLC
3.59%
Janus Henderson Investors
1.97%
其他
79.72%
持股股东
持股股东
占比
Capital World Investors
5.40%
RTW Investments L.P.
4.95%
Fidelity Management & Research Company LLC
4.37%
ClearBridge Investments, LLC
3.59%
Janus Henderson Investors
1.97%
其他
79.72%
股东类型
持股股东
占比
Investment Advisor
16.30%
Investment Advisor/Hedge Fund
16.01%
Hedge Fund
5.50%
Individual Investor
1.74%
Private Equity
1.38%
Venture Capital
1.13%
Research Firm
0.90%
Pension Fund
0.44%
Sovereign Wealth Fund
0.18%
其他
56.42%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
372
46.61M
41.70%
-15.37M
2025Q2
394
60.58M
54.15%
-11.96M
2025Q1
453
59.51M
53.68%
-14.18M
2024Q4
446
60.80M
55.47%
-4.29M
2024Q3
439
51.45M
51.99%
-10.14M
2024Q2
454
47.04M
47.66%
-14.67M
2024Q1
465
46.22M
46.47%
-13.77M
2023Q4
497
46.31M
46.92%
-16.57M
2023Q3
537
44.27M
45.68%
-20.42M
2023Q2
568
47.21M
48.74%
-23.76M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Capital World Investors
6.04M
5.4%
+27.77K
+0.46%
Jun 30, 2025
RTW Investments L.P.
5.54M
4.95%
+2.40M
+76.52%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.89M
4.37%
+206.80K
+4.42%
Jun 30, 2025
ClearBridge Investments, LLC
4.01M
3.59%
+732.39K
+22.33%
Jun 30, 2025
Janus Henderson Investors
2.20M
1.97%
-1.62M
-42.37%
Jun 30, 2025
Baron Capital Management, Inc.
1.59M
1.42%
-241.68K
-13.21%
Jun 30, 2025
Segantii Capital Management Limited
1.56M
1.39%
-131.64K
-7.80%
Mar 31, 2024
Wellington Management Company, LLP
1.38M
1.23%
-2.27M
-62.25%
Jun 30, 2025
Fidelity Institutional Asset Management
1.31M
1.17%
-387.51K
-22.82%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
1.31M
1.17%
+958.14K
+273.75%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Tema Oncology ETF
2.64%
ALPS Medical Breakthroughs ETF
2.2%
Virtus LifeSci Biotech Products ETF
1.31%
Invesco Golden Dragon China ETF
0.84%
National Security Emerging Markets Index ETF
0.46%
iShares Biotechnology ETF
0.25%
Capital Group New Geography Equity ETF
0.18%
ProShares Ultra Nasdaq Biotechnology
0.17%
Invesco Nasdaq Biotechnology ETF
0.16%
ActivePassive International Equity ETF
0.04%
查看更多
Tema Oncology ETF
占比2.64%
ALPS Medical Breakthroughs ETF
占比2.2%
Virtus LifeSci Biotech Products ETF
占比1.31%
Invesco Golden Dragon China ETF
占比0.84%
National Security Emerging Markets Index ETF
占比0.46%
iShares Biotechnology ETF
占比0.25%
Capital Group New Geography Equity ETF
占比0.18%
ProShares Ultra Nasdaq Biotechnology
占比0.17%
Invesco Nasdaq Biotechnology ETF
占比0.16%
ActivePassive International Equity ETF
占比0.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
